Prime Time for Prime Medicine: Gene Editing Startup Raises $315M

Prime Medicine said proceeds from the financing will be used to continue building the company, rapidly advance its gene editing therapy candidates towards clinical indications, and expand the capabilities of its platform. Prime is currently advancing multiple drug discovery programs targeted at liver, eye, ex-vivo hematopoietic stem cell, and neuro-muscular indications.

AI-Driven Drug Discovery Blueprint Could Deliver Better Drugs for Chronic Diseases,...

Researchers at University of California San Diego School of Medicine developed an AI-driven drug discovery approach that uses machine learning to search for disease targets and then predict whether a potential drug is likely to make it through trials to regulatory approval. They say the new approach could provide the “predictive horsepower” to help understand how diseases progress, assess a drug's potential benefits and even strategize how to use a combination of therapies when current treatment is failing.

Nose Drops with Engineered Bacteria Protect against Meningitis

This first of a kind study shows that Neisseria lactamica may be an effective and safe vaccine vector in humans. The commensal bacteria, Neisseria lactamica, when engineered to express a protein from the pathogenic Neisseria meningitidis, elicited immune responses—characterized by both antibody and memory B cell responses—against the protein when introduced into the noses of healthy volunteers via nose drops.

U.S. Special Operations Command to Test Anti-Aging Pill

U.S. Special Operations Command said it has “completed preclinical safety and dosing studies in anticipation of follow-on performance testing” of a first-in-class nicotinamide adenine dinucleotide, oxidized state (NAD+) enhancer, a small molecule drug being developed by Metro International Biotech (MetroBiotech).

FDA Seeks Review of Staff-Biogen Talks Leading to Alzheimer’s Drug Approval

Acting FDA Commissioner Janet Woodcock, MD, cited “concerns raised” about contact between representatives of Biogen and the FDA during the review process for Aduhelm, “including some that may have occurred outside of the formal correspondence process.”

Microbiome Modulates Cancer Immunotherapy for the Better

A team of investigators at the Universities of Würzburg and Marburg have succeeded, for the first time, in experimentally demonstrating that bacterial metabolites can increase the cytotoxic activity of specific immune cells and thus positively influence the efficiency of tumor therapies. Findings from the new study were published recently in Nature Communications.

Study Finds Antibiotic-Resistant “Superbugs” in Dog Foods, Representing International Public Health...

Scientists at the University of Porto found that more than half of the different types of dog food samples they tested contained Enterococci bacteria. More than 20% of the isolates were resistant to linezolid, a "last-resort" antibiotic that is used when all other treatment options have failed, and some of the multidrug-resistant bacteria in raw dog food were identical to those found in hospital patients in different European countries.

Mammalian Stem Cells Harness Same Antiviral Defense Mechanism as Do Plants...

Francis Crick Institute researchers have found that a defense mechanism previously thought to have disappeared in mammals through evolution actively helps to protect mammalian stem cells from RNA viruses such as SARS-CoV-2 and Zika virus. The RNA interference mechanism is used by plants and invertebrates to defend against viruses, but the newly reported studies have now identified a form of Dicer in mammals that specifically protects tissue stem cells from RNA viruses.

The COVID-19 Pandemic: Lessons for the Future

Economic opportunities can be created through paradigm shifts that include acceleration from scientific breakthrough to therapeutic deployment; point-of-care personalized therapeutic design, manufacturing, and delivery; and a unified, proactive approach to pandemic prevention.

Solutions for Improved Work-Life Balance of High-Throughput Bioprocess Development

In this GEN webinar, sponsored by Roche Custom Biotech, we will learn some examples of how bioprocess scientists are taking steps to reduce the weekend lab attendance that has become an unfortunate staple of high throughput projects.
Scroll Up